Short description
Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.
Description
Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.
Last funding
Absolutely Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
New Haven, Connecticut, United States, North America
Founded on
January 1, 2013
Exited on
May 5, 2017
Went public on
May 5, 2017
Stock symbol
BHVN
Non-profit?
No
Acquired?
No
Employees count
1001-5000
Revenue range
$56378 - 90123
Sign in for full access
Investors
Uh Ohhhh, Noway Youcantaccess, Noaccess, Noway Youcantaccess, Noaccessforu, Noway Youcantaccess, Blurry Noaccess, Uh Ohhhh, Noaccess, Noaccess, Nopepepe, Cannot Access, Uh Ohhhh, Absolutely Noaccess, Blurry Noaccess
Sign in for full access
Founders
Rob Berman
Funding rounds count
3
Portfolio organisations count
Nopepepe, Blurry Noaccess
Sign in for full access
Lead investments count
2
Exits count
Absolutely Noaccess, Noaccessforu
Sign in for full access
IPO exits count
1